Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management is a private equity and venture capital firm based in New York, specializing in investments within the life sciences and healthcare sectors. Established in 2017, the firm focuses on various stages of investment, including mezzanine, emerging growth, growth capital, late venture, and mature stage investments. Petrichor aims to support companies involved in diverse areas such as oncology, health technology, artificial intelligence, biopharmaceuticals, medical technology, diagnostics, machine learning, SaaS, and nanotechnology. The firm typically invests between $10 million and $50 million, with the capability to commit larger amounts through co-investments with limited partners. Petrichor Healthcare Capital Management is also a Registered Investment Adviser, providing customized investment structures and support to its portfolio companies.
Ascend supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.
Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.
The company intends to use the funds to conduct market access activities for a number of development projects based on its Stabilizing and Protecting Solutions (SPS®) in the fields of vaccines, biopharmaceuticals and combination devices.
The company intends to use the funds to conduct market access activities for a number of development projects based on its Stabilizing and Protecting Solutions (SPS®) in the fields of vaccines, biopharmaceuticals and combination devices.
ITM Isotopen Technologien München AG, a biotechnology and radiopharmaceutical company, through its subsidiaries, develops, manufactures, and supplies targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides used in cancer treatment. It offers EndolucinBeta, a radiopharmaceutical precursor and indicated for the radiolabeling of disease-specific carrier molecules in nuclear medicine; 225Ac and 213Bi, radionuclide products for the next generation targeted radionuclide therapy; and iQS-TS, an automated cassette-based theranostics synthesizer that facilitates the routine preparation of 68Ga, 177Lu, and 90Y radiolabeled biomolecules. The company also provides iQS® Ga-68, a fluidic labeling module and portable system for the preparation of 68Ga labeled PET/CT tracers; The GMP 68Ga, a chemical set that contains reagents and solvents for the radiolabeling process of DOTA-somatostatin analogs, DKFZ-PSMA-617, and DKFZ-PSMA-11 (HBED-CC); radio-high-performance liquid chromatography system that is used for the assessment of radiopharmaceuticals; and consumables. In addition, it offers GMP radiolabeling services through its laboratories, as well as focuses on developing a portfolio of treatments that address a range of cancers, such as neuroendocrine cancers or bone metastases. ITM Isotopen Technologien München AG was founded in 2004 and is based in Garching, Germany.
ClearPoint Neuro, formerly known as MRI Interventions, is a medical technology company focused on advancing therapies for complex neurological disorders. The company's mission is to enhance the quality of life for patients and their families by enabling precise treatment options. ClearPoint Neuro's current product offerings include solutions for deep-brain stimulation and biopsy procedures. The company is also developing future applications that encompass laser ablation, neuro-aspiration, and the delivery of drugs, biologics, and gene therapies directly to the brain. Through its innovative platform, ClearPoint Neuro aims to provide effective and targeted interventions in the field of neurology.
ClearPoint Neuro, formerly known as MRI Interventions, is a medical technology company focused on advancing therapies for complex neurological disorders. The company's mission is to enhance the quality of life for patients and their families by enabling precise treatment options. ClearPoint Neuro's current product offerings include solutions for deep-brain stimulation and biopsy procedures. The company is also developing future applications that encompass laser ablation, neuro-aspiration, and the delivery of drugs, biologics, and gene therapies directly to the brain. Through its innovative platform, ClearPoint Neuro aims to provide effective and targeted interventions in the field of neurology.
Persivia is a healthcare company that focuses on providing solutions in the healthcare and information technology industry. It specializes in the fields of Chronic Care Management, and Clinical analytics to support ACOs, PCMH.
The company was founded in 2005 and headquartered in Lowell, Massachusetts.
CorneaGen is dedicated to advancing cornea care through the development of innovative medical devices, biologics, and therapeutic interventions aimed at eliminating corneal blindness. The company focuses on transforming the practices of corneal surgeons by providing a comprehensive range of services, including high-quality tissue delivery, surgeon education, and advocacy for patient access and reimbursement. By equipping eye surgeons with the latest tools and resources, CorneaGen enhances their ability to restore sight and improve patient outcomes for those affected by corneal conditions.